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Abstract
Background: Long-term acetate supplementation reduces neuroglial activation and cholinergic cell loss in a rat
model of lipopolysaccharide-induced neuroinflammation. Additionally, a single dose of glyceryl triacetate, used to
induce acetate supplementation, increases histone H3 and H4 acetylation and inhibits histone deacetylase activity
and histone deacetylase-2 expression in normal rat brain. Here, we propose that the therapeutic effect of acetate in
reducing neuroglial activation is due to a reversal of lipopolysaccharide-induced changes in histone acetylation and
pro-inflammatory cytokine expression.
Methods: In this study, we examined the effect of a 28-day-dosing regimen of glyceryl triacetate, to induce
acetate supplementation, on brain histone acetylation and interleukin-1b expression in a rat model of
lipopolysaccharide-induced neuroinflammation. The effect was analyzed using Western blot analysis, quantitative
real-time polymerase chain reaction and enzymic histone deacetylase and histone acetyltransferase assays.
Statistical analysis was performed using one-way analysis of variance, parametric or nonparametric when
appropriate, followed by Tukey’s or Dunn’s post-hoc test, respectively.
Results: We found that long-term acetate supplementation increased the proportion of brain histone H3
acetylated at lysine 9 (H3K9), histone H4 acetylated at lysine 8 and histone H4 acetylated at lysine 16. However,
unlike a single dose of glyceryl triacetate, long-term treatment increased histone acetyltransferase activity and had
no effect on histone deacetylase activity, with variable effects on brain histone deacetylase class I and II expression.
In agreement with this hypothesis, neuroinflammation reduced the proportion of brain H3K9 acetylation by 50%,
which was effectively reversed with acetate supplementation. Further, in rats subjected to lipopolysaccharide-
induced neuroinflammation, the pro-inflammatory cytokine interleukin-1b protein and mRNA levels were increased
by 1.3- and 10-fold, respectively, and acetate supplementation reduced this expression to control levels.
Conclusion: Based on these results, we conclude that dietary acetate supplementation attenuates neuroglial
activation by effectively reducing pro-inflammatory cytokine expression by a mechanism that may involve a distinct
site-specific pattern of histone acetylation and histone deacetylase expression in the brain.
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Background
Reversible epigenetic changes play a major role in regu-
lating gene expression in the post-mitotic brain. The
most prominent mechanism involved in this process is
the alteration in histone acetylation, which is known to
influence development, differentiation and the injury
response [1]. Therefore, understanding the functional
consequences of changes in histone acetylation in the
brain is important given the impact that it can have on
neuroinflammation. Histone proteins are instrumental in
the packaging of DNA and play a central role in tran-
scription through a process of acetylation that regulates
the accessibility of DNA to proteins involved in tran-
scription. As a general consensus, an increase in histone
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while a decrease in histone acetylation is associated with
gene repression [2,3]. In this regard, site-specific acetyla-
tion patterns have been linked to both physiological and
pathological roles. For example, histone H4 acetylated at
lysine 16 (H4K16) is essential for transcription initiation
[4] and DNA repair [5]. Histone H3 acetylated at lysine
9 (H3K9) is selectively enriched at the promoters of
stem cells, suggesting a role in pluripotency [6].
The histone acetylation state is actively maintained by
the opposing activities of two enzyme families: histone
acetyltransferases (HATs) and histone deacetylases
(HDACs). Based on structural homology, HDACs are
classified into different classes: HDAC class I are mainly
located in the nucleus, HDAC class II shuttle between
the nucleus and cytoplasm [7]a n dH D A Cc l a s sI I I( s i r -
tuins) are located in the cytoplasm. HDAC classes I and
II are inhibited by conventional HDAC inhibitors while
class III HDACs are nicotinamide adenine dinucleotide
(NAD
+)-dependent and inhibited by nicotinamide [8].
Likewise, HAT are classified into distinct families (gen-
eral control non-derepressible 5 (GCN5), P300/cyclic
adenosine monophosphate response element binding
protein associated factor (PCAF), the MYST family
named for its founding members in yeast and mammals,
monocytic leukemia zinc finger protein (Moz), Some-
thing About Silencing protein (Sas2p), and HIV tat-inter-
acting protein 60 (Tip60), transcription initiation factor
TFIID 250 kDa subunit (TAFII250), steroid receptor
coactivator proteins (SRC), and GCN5-related N-acetyl-
transferase (GNAT)) that show high sequence similarity
within families, but poor-to-no sequence similarity
between families [9]. The exact correlation of individual
HAT or HDAC with site-specific acetylation or deacety-
lation of histone lysine residues remains largely unknown
due to overlapping enzyme targets [10,11].
Lipopolysaccharide (LPS), an endotoxin present in the
membrane of Gram-negative bacilli, binds to toll-like
receptor 4 found on brain microglia and promotes an
inflammatory response characterized by the enhanced
expression of the pro-inflammatory cytokine IL-1b, neu-
roglial activation and neurodegeneration [12-14]. LPS
infusion through a cannula implanted into the fourth
ventricle of the brain and connected to a subcutaneous
mini-osmotic pump is used as a model to study neuroin-
flammation in rats [15-17]. In this model, the turnover
and metabolism of brain arachidonic acid is increased by
40%, the activities of both arachidonic acid-selective
secretory and cytosolic phospholipases A2 increase, as do
the levels of prostaglandins E2 and D2 [18,19]. Thus, this
model reproduces many of the properties associated with
known modalities of neuroinflammation.
We have demonstrated in this model that acetate sup-
plementation, using glyceryl triacetate (GTA), increases
brain acetyl-coenzyme A (CoA) levels two-fold and
attenuates both neuroglial activation and cholinergic cell
loss [17]. Dietary acetate supplementation is suggested
as a potential therapy for Canavan’s disease [20], is
effective in alleviating tremors in a rat model of Cana-
van’s disease [21] and is neuroprotective in a rat model
of traumatic brain injury [22]. A single oral dose of
GTA given to normal rats differentially increases the
proportion of acetylated brain H3K9, H4 acetylated at
lysine 8 (H4K8) and H4K16, with no changes in the
acetylation state of histone H3 acetylated at lysine 14
(H3K14), histone H4 acetylated at lysine 5 (H4K5) or
histone H4 acetylated at lysine 12 (H4K12). It also
decreases brain HDAC activity and HDAC2 expression
with no changes in brain HAT activity [23].
Since an increase in histone acetylation correlates with
anti-inflammatory response and neuroprotection [24,25],
and because acetate supplementation alters brain histone
acetylation, we propose that long-term acetate supplemen-
tation reduces neuroglial activation and cholinergic cell
loss by modulating the brain histone acetylation state and
pro-inflammatory cytokine expression. This hypothesis is
based on the premise that the innate immune response in
the brain is dependent on the communication between
neuroglia and that an increase in pro-inflammatory cyto-
kine expression will result in heightened microglial and
astroglial activation [26]. To begin to test this hypothesis,
we quantified the effect that a 28-day-dosing regimen of
GTA, used to induce acetate supplementation, had on the
brain histone acetylation state, HAT and HDAC enzymic
activities, and the expression of the pro-inflammatory
cytokine IL-1b. We found that long-term acetate supple-
mentation reversed the LPS-induced decrease in H3K9
acetylation, increased HAT enzymic activity and reduced
IL-1b expression in the brain. These results support our
hypothesis that long-term acetate supplementation can
attenuate LPS-induced changes in histone acetylation and
reduce pro-inflammatory gene expression in the brain.
The mechanism by which acetate supplementation
reduces pro-inflammatory gene expression and neuroglial
activation, however, remains to be determined.
Methods
Reagents
Antibodies against total histone H3 and H4, and acetylated
histone isoforms H3K9, H3K14, H4K5, H4K8, H4K12 and
H4K16 were purchased from Upstate Biotechnology (Lake
Placid, NY, USA). Antibodies against HDAC1, 2, 3, 4, 5
and 7 were obtained from Cell Signaling Technology Inc.
(Danvers, MA, USA). A rabbit polyclonal antibody to IL-
1b was purchased from Abcam (Cambridge, MA, USA),
and an antibody against a-tubulin and goat anti-mouse
immunoglobulin M secondary antibody conjugated with
horseradish peroxidase (HRP) were from Santa Cruz
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blot supplies and a goat anti-rabbit HRP-linked antibody
were obtained from Bio-Rad Laboratories (Hercules, CA,
USA). IL-1b and b-actin primers (mix of reverse and for-
ward primers) were purchased from SA Biosciences
(Frederick, MD, USA); FastStart Universal SYBR Green
Master was purchased from Roche Applied Science (India-
napolis, IN, USA); an iScript cDNA synthesis kit was pur-
chased from Bio-Rad Laboratories; TRIzol
® reagent was
purchased from Life Technologies (Grand Island, NY,
USA); and nuclease-free water was purchased from Gibco,
Life Technologies. Buffering reagents and other chemicals
were purchased from EMD Biosciences (Gibbstown, NJ,
USA) unless noted otherwise, and GTA was purchased
from Sigma (St. Louis, MO, USA).
Animal surgeries and induction of neuroinflammation
The treatment of all rats used in this study conformed to
the Guide for the Care and Use of Laboratory Animals
(National Institutes of Health publication number 80-23)
as approved by the University of North Dakota animal
care and use committee. Male Sprague-Dawley rats (200
to 250 g; Charles River Laboratories, Portage, MI, USA)
were allowed to acclimate in our facility for at least two
weeks prior to inclusion in the study and were main-
tained on a constant 12-hour light cycle and fed a stan-
dard laboratory chow (Purina 2018 Teklad Global) ad
libitum. Rats were starved for at least 12 hours before
surgeries and the first treatment with either GTA or
water to normalize circulating levels of glucose and fatty
acids [27].
In order to induce neuroinflammation, animals had
cannulas (Model 3280PM, Plastics One, Roanoke, VA,
USA) connected to subcutaneous osmotic mini-pumps
(Model 2004, Durect Corporation, Cupertino, CA, USA)
surgically implanted into the fourth ventricle of the brain
as previously described [17]. The concentration of endo-
toxin used in these studies (5.0 ng/hour) was based on
data showing that this concentration results in significant
neuroglial activation and cholinergic cell loss above con-
trol rats [17], and is consistent with previous studies
demonstrating a selective increase in arachidonic acid
metabolism using this model [18,19]. During the infusion
period, rats were treated daily with either GTA or water
a tad o s eo f6g / k gb yg a s t r i cg a v a g eu s i n gf e e d i n gt u b e s
(Instech Solomon, Plymouth, PA, USA). The rats used
for histone acetylation analysis were divided into four dif-
ferent groups: group one (n = 8) received an artificial cer-
ebral spinal fluid (aCSF) infusion and were treated daily
with water for 28 days (aCSF + H2O); group two (n = 7)
received an aCSF infusion and daily treatment with GTA
for 28 days (aCSF + GTA); group three (n = 8) received
an LPS infusion and daily treatment with water for 28
days (LPS + H2O); and group four (n = 5) received an
LPS infusion and daily treatment with GTA for 28 days
(LPS + GTA). The rats used for IL-1b analysis were
divided into three different treatment groups: group one
(n = 6) received an aCSF infusion (aCSF), group two (n =
12) received an LPS infusion (LPS), and group three (n =
6) received an LPS infusion and daily treatment with
GTA for 28 days (LPS + GTA). On the 28
th day of treat-
ment, animals were anesthetized with isoflurane (Butler
Animal Health Supply, Dublin, OH, USA) in an induc-
tion chamber for 1 minute and then killed by decapita-
tion. Brains were immediately removed and flash-frozen
by immersing in liquid nitrogen. The postmortem inter-
vals for the brain did not exceed 1 minute. All samples
were stored at -80°C until used.
Tissue extraction
The nuclei isolation and acid extraction of histones were
performed as described previously [23]. Rat brains used to
measure IL-1b levels were homogenized using an ultraso-
nic dismembrator (Fisher Scientific, Waltham, MA, USA)
in ice-cold 50 mM tris(hydroxymethyl)aminomethane
(Tris; pH 7.4) buffer containing 150 mM sodium chloride,
1 mM ethylene glycol tetraacetic acid, 1 mM sodium
orthovanadate, 5 mM zinc chloride, 10 mM sodium fluor-
ide, 1 mM phenylmethylsulfonyl fluoride, Complete, ethy-
lenediaminetetraacetic acid-free protease inhibitor cocktail
(Roche Applied Science, Indianapolis, IN, USA), and 0.1%
Igepal CA-630 as previously described [28]. The cytosolic
portion of the samples was isolated by centrifugation at
4°C for 20 minutes (4,500 × g) [29].The cytosolic fractions
were stored at -80°C until use. Protein concentration
w a sm e a s u r e du s i n gt h eB r a d f o r dm e t h o dw i t hB S Aa s
standard [30].
Western blot analysis
Equal amounts of protein; 5 μg for brain H3, 3.5 μgf o r
brain H4, 50 μgf o rb r a i nI L - 1 b and 4 μgf o ra l lb r a i n
HDAC were prepared by boiling samples in loading buffer
composed of 95% Laemmli sample buffer and 5% 2-mer-
captoethanol (Sigma). The separation of histones was per-
formed using a 10% to 20% Tris-hydrochloride (Tris HCl)
gel, the different HDACs on a 15% Tris-HCl gel and IL-1b
on a 15% Tris-HCl gel with an electrophoresis separation
of 100 volts for 2 hours. The electrophoretic transfer of
proteins onto a 0.45-μm nitrocellulose membrane was per-
formed at 100 volts for 90 minutes on ice. Primary antibo-
dies were prepared in Tris-buffered saline containing
Tween (TTBS; 20 mM Tris buffer, pH 7.4, 150 mM
sodium chloride, 0.05% Tween 20) and 5% non-fat dried
milk. The antibody concentrations used were: total H4,
1:1000; acetylated H4K5, 1:1000; acetylated H4K8, 1:1000;
acetylated H4K12, 1:1000; acetylated H4K16, 1:1000; total
H3, 1:500; acetylated H3K9, 1:800; acetylated H3K14,
1:1000; IL-1b, 1:5000; a-tubulin, 1:1500; and HDAC1, 2, 3,
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with the nitrocellulose membranes overnight at 4°C. The
blots probed for all histones and HDAC5 and HDAC7
were conjugated with a HRP-linked goat anti-rabbit sec-
ondary antibody, and their dilutions were 1:3000 in TTBS
for all histone blots and 1:1000 in TTBS for HDAC5 and
HDAC7 blots. The blots probed with primary HDAC1, 2,
3 and 4 antibodies were conjugated with a horse anti-
mouse, HRP-linked secondary antibody at a dilution of
1:1000. For the detection of IL-1b, the HRP-linked second-
ary antibody dilution was set at 1:20,000. The blots probed
with a-tubulin antibody were conjugated with a HRP-
linked goat anti-mouse immunoglobulin M secondary
antibody at a dilution of 1:2000 in TTBS. Bands were
visualized with a SuperSignal
® West Pico or West Femto
Chemiluminescent Substrate (Pierce, Rockford, IL, USA)
using a UVP Bioimaging System (Upland, CA, USA).
Image capturing and analysis was performed with Lab-
Works™ imaging software (version 4.5; UVP). Western
blot data of acetylated histones is expressed as of the ratio
of the optical density of acetylated histone residues to the
optical density of total histone. Western blot data of
HDAC is expressed as the ratio of the optical density of
the respective HDAC to the optical density of the loading
control a-tubulin. Western blot data of IL-1b is expressed
as the ratio of the optical density of IL-1b to the optical
density of the loading control Ponceau S.[31]
Quantitative real-time polymerase chain reaction
Brain cortex samples (50 to 100 mg each) were homoge-
nized in 1 mL TRIzol
® reagent, using a Polytron homoge-
n i z e r .H o m o g e n i z e ds a m p l e sw e r ei n c u b a t e da tr o o m
temperature for 5 minutes to permit the dissociation of
nucleoprotein complexes before adding 0.2 mL of chloro-
form, shaking the tubes vigorously by hand, and incubat-
ing again at room temperature for 3 minutes. The samples
were then centrifuged at 12,000 × g for 10 minutes at 4°C.
After centrifugation, the upper clear aqueous phase con-
taining RNA was transferred to fresh tubes, where the
RNA was precipitated from the aqueous phase by mixing
with 0.5 mL of isopropyl alcohol. The mix was incubated
at room temperature for 10 minutes then centrifuged at
12,000 × g for 10 minutes at 4°C. The RNA pellet was
washed once with 1 mL of 75% ethanol and centrifuged at
7 , 5 0 0×gf o r5m i n u t e sa t4 ° C .A tt h ee n do ft h eR N A
extraction, the ethanol was decanted and the RNA pellet
was allowed to air-dry at room temperature for 5 minutes
before re-dissolving in 200 μL of nuclease-free water. One
microgram of RNA per sample was used for cDNA synth-
esis using the iScript cDNA synthesis kit according to the
manufacturer’s instructions. Amplification was performed
using 500 ng cDNA, 500 nM of each of the reverse and
forward IL-1b and b-actin primers, and FastStart Universal
SYBR Green Master in a final reaction volume of 50 μL,
using a two-step cycling program of one cycle of 95°C for
10 minutes followed by 40 repeats of 95°C for 15 seconds
and 60°C for 60 seconds in iCycler iQ Multicolor Real-
Time PCR Detection System (Bio-Rad). The expression of
IL-1b transcript amplified was normalized to the expres-
sion of b-actin. The amplification product was mixed with
DNA Gel loading buffer 10 × (5 Prime, Gaithersburg, MD,
USA), and run on 1% agarose gel at 100 volts for 1 hour.
AT r a c k I t ™ DNA ladder (Invitrogen, Grand Island, NY,
USA) was used. PCR quantification was performed using
the Livak formula [32].
Histone deacetylases and histone acetyltransferases and
activity assays
HDAC and HAT activities in the brain were measured
using the colorimetric HDAC activity assay kit (Millipore,
Billerica, MA, USA) and HAT activity assay kit (Abcam),
respectively, according to the manufacturers’ instructions
and as described previously [23]. The colorimetric HDAC
assay measures the total HDAC activity in a two-step pro-
cedure performed in a 96-well plate. In the first step, sam-
ples were incubated with the HDAC assay substrate,
allowing deacetylation of the substrate. Next, the addition
of an activator solution released p-nitroanilide from the
deacetylated substrate or standard, monitored by spectro-
photometric analysis. The colorimetric HAT activity assay
depends on the acetylation of a peptide substrate by the
active HAT; a process associated with the release of the
free form of CoA. CoA serves as an essential coenzyme for
the production of reduced nicotinamide adenine dinucleo-
tide (NADH), which is measured using spectrophoto-
metric analysis upon its reaction with a soluble
tetrazolium dye. HDAC activity is expressed as the ratio of
absorbance at 405 nm after 75 minutes of incubation at
37°C, normalized to the amount of nuclear extract used.
HAT activity is expressed as the ratio of the absorbance at
450 nm after 4 hours of incubation at 37°C, normalized to
the amount of nuclear extract used.
Statistical analysis
A parametric one-way analysis of variance (ANOVA)
followed by Tukey’s post-hoc test or nonparametric
one-way ANOVA followed by Dunn’sp o s t - h o ct e s t
were used as appropriately indicated to calculate statisti-
cal differences using GraphPad InStat statistical software
(Version 3.06 for Windows, San Diego, CA, USA). All
results are expressed as means ± SD with the signifi-
cance threshold set at P ≤ 0.05.
Results
Acetate supplementation and brain histone H3 and
histone H4 acetylation
The proportions of acetylated histone H3 and H4 were
measured using Western blot analysis. Total H3,
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protein bands corresponding to a molecular weight of
17 kDa (Figure 1A). Optical density analysis of acety-
lated H3 showed a 1.6-fold increase in the proportion of
H3K9 in the two groups of rats subjected to acetate
supplementation (aCSF + GTA) and (LPS + GTA), com-
pared to controls (aCSF + H2O) (Figure 1B). Interest-
ingly, the proportion of acetylated H3K9 was decreased
by 2-fold in rats subjected to neuroinflammation and
treated with water (LPS + H2O )a n d3 - f o l dw h e nc o m -
pared to rats that received acetate (aCSF + GTA and
LPS + GTA). Neither acetate supplementation nor neu-
roinflammation altered the acetylation state of brain
H3K14.
Total H4 and acetylated H4K5, H4K8, H4K12 and
H4K16 were detected as a protein bands at 10 kDa which
correspond to the molecular weight of these histones
(Figure 2A). Similar to the proportional increases in
acetylated H3K9, the proportions of acetylated H4K8 and
H4K16 were significantly increased by 2-fold in rats sub-
jected to acetate supplementation (aCSF + GTA and LPS
+ GTA; Figure 2B). However, unlike the proportion of
acetylated H3K9, the proportion of acetylated H4K8 and
H4K16 were not decreased in the rats subjected to neu-
roinflammation and treated with water (LPS + H2O)
when compared to controls (aCSF + H2O). Neither acet-
ate supplementation nor neuroinflammation altered the
acetylation state of H4K5 or H4K12. These results sug-
gest that acetate supplementation can selectively and
positively regulate the acetylation of both histone H3 and
H4 at specific acetylation sites. However, LPS-induced
neuroinflammation only decreased the acetylation state
of H3K9, which was effectively reversed with acetate
supplementation.
Acetate supplementation and brain histone deacetylase
and histone acetyltransferase activities
Because the brain histone acetylation state is controlled by
the activities of HAT and HDAC, we examined the effect
that acetate supplementation had on brain HAT and
HDAC activities in different test groups. Using commer-
cially available HDAC and HAT assay kits, we found that
acetate supplementation significantly increased, by 1.8-
and 1.6-fold, the activity of brain HAT in the aCSF + GTA
and LPS + GTA groups, respectively, compared to control
aCSF + H2O rats (Figure 3). No changes in HAT activity
were observed in rats subjected to neuroinflammation and
treated with water (LPS + H2O). The HAT activity in the
control sample was 35 ± 12 AU at 450 nm/ng protein,
while the HAT activities in the aCSF + GTA and the
LPS + GTA groups were 62 ± 14 and 56 ± 10 AU at
450 nm/ng protein, respectively. In parallel experiments,
we did not find any changes in brain HDAC activity in
any of the groups tested. These results suggest that long-
term acetate supplementation, and not LPS-induced neu-
roinflammation, positively regulates brain HAT activity
with no apparent effect on brain HDAC activity.
Acetate supplementation and brain histone deacetylase
expression
In an earlier study we found that a single oral dose of
GTA decreases HDAC activity and reduces the expres-
s i o no fH D A C 2[ 2 3 ] .I nt h ec u r r e n ts t u d y ,h o w e v e r ,w e
did not observe changes in HDAC activity, suggesting
that the effects of long-term treatment differ substantially
from a single oral dose. In order to further understand
the effect that long-term acetate supplementation has on
HDAC expression, we measured changes in the indivi-
dual HDAC levels using western blot analysis. Optical
density analysis showed that HDAC1 expression was sig-
nificantly elevated by 2.4- and 1.7-fold in rats treated
with GTA (aCSF + GTA and LPS + GTA; Figure 4B). A
similar effect was found in HDAC2 expression where the
level was significantly increased by 1.7-fold in rats treated
with acetate (aCSF + GTA), but not in rats subjected to
neuroinflammation (LPS + GTA). The expression levels
of HDAC1 and HDAC2 were not altered by LPS-induced
neuroinflammation treated with water (LPS + H2O). On
the contrary, the levels of HDAC3 were significantly
decreased by 40% in rats treated with acetate, (aCSF +
GTA and LPS + GTA) as compared to control rats (aCSF
+H 2O). The HDAC3 expression level was not altered in
rats subjected to neuroinflammation treated with water
(LPS + H2O) as compared to control rats (aCSF + H2O).
Most interestingly, the expression of HDAC7 was
increased by 1.7-fold in rats subjected to neuroinflamma-
tion and treated with water (LPS + H2O), which was
effectively reversed with acetate supplementation (aCSF
+ GTA and LPS + GTA). No changes were found in the
expression levels of HDAC4 and HDAC5 in any of the
groups tested. These results suggest the HDAC7 may
play a positive role in the inflammatory process evoked
by long-term LPS infusion that does respond to long-
term acetate supplementation.
Acetate supplementation and brain interleukin-1b
expression
To test whether acetate supplementation can reduce the
expression of pro-inflammatory cytokines, and to provide
insight into the anti-inflammatory mechanism by which
acetate supplementation is effective in this model of neu-
roinflammation, we measured the effect that acetate
treatment has on the protein and mRNA levels of brain
pro-inflammatory cytokine IL-1b. In these experiments,
we found protein bands corresponding to a molecular
weight of 17 kDa corresponding to IL-1b (Figure 5A),
and cDNA bands corresponding to 209 and 131 base
pairs which correspond to the expected base pair size of
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Page 5 of 14Figure 1 Changes in the acetylation state of brain H3K9, and H3K14 in control rats (aCSF), rats subjected to neuroinflammation (LPS)
and rats treated with either water (H2O) or glyceryl triacetate (GTA). (A) Representative images of the western blots. (B) Averaged
proportion of brain H3K9 and H3K14, normalized to total H3. The data represent the means ± SD where statistical significance (a = compared to
aCSF + H2O, and b = compared to LPS + H2O) was set at P ≤ 0.05, as determined by one-way ANOVA followed by Tukey’s post-hoc test.
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Page 6 of 14Figure 2 Changes in the acetylation state of brain H4K5, H4K8, H4K12 and H4K16 in control rats (aCSF), rats subjected to
neuroinflammation (LPS) and rats treated with either water (H2O) or glyceryl triacetate (GTA). (A) Representative images of the western
blots (B) Averaged proportion of brain H4K5, H4K8, H4K12 andH4K16, normalized to total H4. The data represent the means ± SD where
statistical significance (a = compared to aCSF + H2O, and b = compared to LPS + H2O) was set at P ≤ 0.05, as determined by one-way ANOVA
followed by Tukey’s post-hoc test.
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Page 7 of 14IL-1b and b-actin, respectively (Figure 5C). In rats sub-
jected to neuroinflammation (LPS + H2O), IL-1b protein
and mRNA levels were significantly elevated by 1.3- and
10-fold, respectively, (Figure 5B,D). Further, the long-
term acetate supplementation significantly reduced the
expression level of IL-1b below that found in rats
subjected to neuroinflammation (LPS), and equal to the
control levels (aCSF).
Discussion
Understanding the functional consequences of altera-
tions in histone acetylation in the post-mitotic brain is
Figure 3 The effect of long-term acetate supplementation on brain histone deacetylase and histone acetyltransferase activities in
control rats (aCSF), rats subjected to neuroinflammation (LPS) and rats treated with either water (H2O) or glyceryl triacetate (GTA). (A)
Represents changes in brain HAT, and (B) represents changes in HDAC activities. HAT enzyme activity is expressed as the means ± SD of
absorbance reading at 450 nm after 4 hours of incubation at 37°C, normalized to the protein assayed (μg). HDAC enzyme activity is expressed as
the means ± SD of absorbance at 405 nm after 75 minutes of incubation at 37°C, normalized to the protein assayed (μg). Statistical significance
(*compared to aCSF + H2O controls) was set at P ≤ 0.05, as determined by nonparametric one-way ANOVA followed by Dunn’s post-hoc test.
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gression and resolution. We have found that long-term
dietary acetate supplementation decreases neuroglia acti-
vation and cholinergic cell loss in a rat model of neu-
roinflammation [17] and that a single dose increases
histone acetylation, decreases HDAC activity and
decreases HDAC2 expression [23]. Because histone
hyperacetylation is anti-inflammatory [24] and can alter
gene expression [3], we propose that dietary acetate is
anti-inflammatory by reducing pro-inflammatory gene
expression. To begin to test this hypothesis we quanti-
fied the ability of long-term acetate supplementation to
Figure 4 The effect of long-term acetate supplementation on the expression of individual brain histone deacetylase in control rats
(aCSF), rats subjected to neuroinflammation (LPS) and rats treated with either water (H2O) or glyceryl triacetate (GTA). (A)
Representative images of the western blots. (B) Quantifications of HDAC1, 2, 3, 4, 5 and 7. Data in B represent means ± SD of the optical
densities normalized to a-tubulin. Statistical significance (* compared to aCSF + H2O controls) was set at P ≤ 0.05, as determined by one-way
ANOVA followed by Tukey’s post-hoc test for HDAC2, 3, 4 and 5, and nonparametric one-way ANOVA followed by Dunn’s post-hoc test for
HDAC1 and 7.
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Page 9 of 14Figure 5 The effect of long-term acetate supplementation on the expression of brain IL-1b in control rats (aCSF), rats subjected to
neuroinflammation (LPS) and rats treated with either water (H2O) or glyceryl triacetate (GTA) as determined by Western blot analysis
and quantitative real-time PCR. (A) Western blot representative images of bands for IL-1b and a-tubulin and (B) shows the means ± SD of
the normalized optical density of IL-1b protein. (C) Representative images of the bands for IL-1b and b-actin cDNA and (D) shows the means ±
SD of the normalized amplified IL-1b cDNA. Statistical significance (a = compared to aCSF + H2O, and b = compared to LPS + H2O) was set at P
≤ 0.05 (n = 6, per group), as determined by a one-way ANOVA followed by Tukey’s post-hoc test.
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Page 10 of 14increase brain histone acetylation, to alter HAT and
HDAC activities, and measured its ability to decrease
the expression of the pro-inflammatory cytokine IL-1b.
Unlike a single dose of GTA, long-term acetate supple-
mentation increased HAT activity and had no effect on
total brain HDAC activity, with variable effects on brain
HDAC class I and II expression. In agreement with our
hypothesis, neuroinflammation reduced the proportion
of brain H3K9 acetylation by 50% and increased IL-1b
protein and mRNA levels by 1.3- and 10- fold, respec-
tively, all of which were effectively reversed with long-
term acetate supplementation.
The preferential hyperacetylation of brain H4K16 is
recognized as a central switch in higher-order chromatin
structure [4]. When arranged into nucleosomal arrays,
acetylated H4K16 inhibits the formation of higher-order
30-nm chromatin fibers and activates gene expression.
The acetylation state at H4K16 is also an epigenetic hall-
mark for certain cancers, including leukemia, lymphoma
and colorectal adenocarcinoma cell lines, in which
H4K16 hyperacetylation is lost [33,34]. Moreover, H4K16
a c e t y l a t i o ni st h o u g h tt op l a yau n i q u er o l ei nD N A
repair as it is defective in aging and neurodegenerative
disorders [5]. In this regard, both H4K16 and H4K8 acet-
ylation were increased after acetate supplementation.
These results suggest that acetate supplementation may
be effective at attenuating neuroinflammation by altering
higher-order chromatin structure and reducing pro-
inflammatory gene expression. In support of this notion,
H4K12 acetylation, which was not altered in our model,
is implicated in gene silencing [35]. Therefore, these data
suggest that LPS-induced neuroinflammation and acetate
treatment do not silence gene expression, but rather shift
gene expression to either a more pro- or anti-inflamma-
tory state, respectively.
The effect of neuroinflammation on brain histone acet-
ylation in parallel with the drug effect found in the con-
trol and treated rats suggest that H3K9 acetylation and
possibly HDAC7 activity may be directly involved in
injury progression in this model. For example, as outlined
in Figure 1, LPS-induced neuroinflammation resulted in a
direct reduction in H3K9 acetylation that was reversed
with acetate supplementation. This finding is corrobo-
rated by the work of Zhang et al. showing that the use of
an HDAC inhibitor 4-dimethylamino-N-[5-(2-mercap-
toacetylamino) pentyl] benzamide (DMA-PB) decreases
microglial activation in a rat model of traumatic brain
injury, and that this anti-inflammatory effect is associated
with increased histone H3 acetylation [36]. Further, the
proportion of acetylated H3K9 is significantly lower in
livers of aged rats, suggesting that the acetylation of
H3K9 may be required to maintain essential cellular
functions [37]. Similarly, we found that the expression of
HDAC7 was increased in rats subjected to LPS-induced
neuroinflammation, and was again reversed with long-
term acetate supplementation. This suggests that
mechanisms are in place that may account for injury-
and treatment-specific changes in histone acetylation. In
contrast, the acetylation state of H3K14 was not altered
by acetate supplementation or LPS-induced neuroinflam-
mation, suggesting that H3K14 acetylation was not
related to treatment or neuroinflammation.
Another discrepancy between the effects of a single oral
dose of acetate versus long-term acetate supplementation
is that a single treatment decreases brain HDAC activity,
whereas long-term supplementation had no effect on
total brain HDAC activity, despite multiple alterations in
the expression of individual HDAC. This can be
explained by the fact that HDAC assays performed in
this study measured overall HDAC activity and were
reflective of the sum of all the individual HDAC. Given
the differences in HDAC expression (that is, increased
brain HDAC1, 2 and 7 and decreased brain HDAC3), we
believe that the histone acetylation pattern found in this
study is a reflection of the substrate specificity of the spe-
cific HDAC expressed after treatment, despite no overall
change in total brain HDAC activity. We speculate that
the increased expression of HDAC1 and HDAC2 is a
physiological response to long-term acetate supplementa-
tion and an increase in brain acetyl-CoA levels. Further,
HDAC activity does not depend solely on the expression
HDAC, but rather works in concert with co-regulatory
repressive complexes to modify catalytic activity [7]. For
example, cloned HDAC and purified HDAC do not have
deacetylating activity in vitro due to the lack of other pro-
tein complexes found in vivo [ 3 8 ] .T h e r e f o r e ,H D A C
activity is not expected to increase unless the increase in
HDAC expression is paralleled by an increase in the
expression of co-regulatory complexes. Moreover, we do
not exclude the possibility that other post-transcriptional
or post-translational modifications of the expressed
HDAC render them less active, resulting in no overall
change in total brain HDAC activity.
To address non-specific effects of acetate on gene
expression, we performed an RT-PCR array to determine
the simultaneous changes in 84 genes involved in both the
innate and adaptive immune response. In this study we
found no significant changes (> 0.5-fold) in the expression
of 81 genes measured. However, three genes did show
more than a 2-fold change; adenosine receptor 2a, caspase
4 and IL-1 receptor antagonist (data not shown), suggest-
ing that acetate supplementation can influence the expres-
sion of other genes involved in adaptive and innate
immune responses. Clinical trials using GTA to induce
acetate supplementation in patients with Canavan’s disease
show that it does not produce biochemical or metabolic
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Page 11 of 14abnormalities [39,40] and animal studies using larger
doses of GTA are well-tolerated and cause no apparent
toxicity [20].
IL-1b, among other cytokines, is expressed in the brain
at low levels under physiological conditions and contri-
butes to the control of metabolism [41], temperature regu-
lation [42], synaptic plasticity and neuronal transmission
[43]. However, IL-1b is produced in high levels in many
pathological conditions that include ischemic stroke [44],
Alzheimer’s disease [45,46], Down syndrome [45], multiple
sclerosis [47], Parkinson’s disease [48], epilepsy [49],
amyotrophic lateral sclerosis [50] and HIV-associated
dementia [51]. This suggests that IL-1b has an important
role in the progression of neuroinflammation [52]. Upon
injury, activated microglia produce inflammatory media-
tors which lead to activation and proliferation of astro-
cytes. Likewise, activated astrocytes release inflammatory
mediators, leading to further inter-glial communication,
that if left unchecked results in neuronal bystander lysis
[26]. IL-1b is a major signaling molecule and is involved in
both neuronal-glial and inter-glial interactions that can
increase microglial proliferation in mixed glial cultures,
but not in isolated microglial cultures [53], bolstering the
notion that microglial activation is at least in part depen-
dent on interactions with neighboring astrocytes [54].
Therefore, disruption of the IL-1b system using anti-IL-1b
antibodies, receptor blockade, or interfering with activa-
tion by enzymatic cleavage ameliorates neuroinflammation
and delays neurodegeneration [55].
In this regard, in a mouse model of septic shock, the his-
tone deacetylase inhibitor suberoylanilide hydroxamic acid
(SAHA) increases H3K9 acetylation and inhibits TNF-a
and IL-1b gene expression in lung tissue [56]. This sup-
ports the premise that the reduction in the proportion of
H3K9 is indeed associated with the LPS-induced neuroin-
flammation, and that increased H3K9 acetylation can be
linked to reducing the pro-inflammatory cytokine IL-1b
expression. However, IL-1b expression in microglia is con-
trolled directly by p38a mitogen-activated protein kinase
(MAPK) downstream of the toll-like receptor 4 complex
and is modulated by inhibitors selective for this kinase
[57]. Further, p38a MAPK is associated with other regula-
tory kinases that are potentially modified post-transcrip-
tion by acetylation reactions. For example, HDAC
inhibition increases the acetylation of mitogen-activated
protein kinase phosphatase-1 (MKP-1) that promotes
complex formation between MKP-1 and p38a MAPK.
This results in a reduction in phosphorylated p38a MAPK
and a reduction in cytokine formation [58]. Mechanisti-
cally, it is not known whether the net anti-inflammatory
effect of HDAC inhibition is the result of alterations in
pro-inflammatory gene expression or a direct result of
modulating the acetylation-state of accessory proteins
involved in toll-like receptor signaling. In this regard,
HDAC7 activity was increased in rats subjected to neu-
roinflammation and was effectively reversed by acetate
supplementation. Therefore, it is not clear at this point as
to whether the treatment effect found in this study on IL-
1b expression is a direct result of decreasing p38a MAPK
phosphorylation or an indirect effect by modulating gene
expression.
Another metabolite that has anti-inflammatory and
neuroprotective properties is pyruvate. The supplementa-
tion of pyruvate, or its aliphatic ester ethyl pyruvate,
decreases LPS and hydrogen peroxide-induced microglial
activation and promotes neuronal survival [59]. In addi-
tion, the administration of pyruvate provides protection
against hippocampal neuronal injury after transient cere-
bral ischemia in rats [60]. Pyruvate also boosts extracellu-
lar brain glucose levels and decreases contusion volume
and neuronal death in a rat model of traumatic brain
injury [61]. Because acetate-derived acetyl-CoA can inhi-
bit pyruvate dehydrogenase and lead to the accumulation
of brain pyruvate, it is not unreasonable to suggest that
the anti-inflammatory and neuroprotective effects of
acetate may occur due to the accumulation of pyruvate.
It will be interesting to test whether pyruvate, like acet-
ate, can increase brain acetyl-CoA levels and alter histone
acetylation and pro-inflammatory gene expression.
To examine whether acetate works through a mito-
chondrial process, we measured the effect of acetate on
mitochondrial biogenesis but found no alteration in
neuronal mitochondrial numbers after 28 days of acetate
supplementation (unpublished data). This, however,
does not exclude the possibility that acetate alters other
mitochondrial processes such as the tricarboxylic acid
cycle, the energy state or mitochondrial gene expression.
Conclusion
In conclusion, long-term acetate supplementation
reduced IL-1b expression by a mechanism that may
involve a distinct site-specific pattern of histone acetyla-
tion and/or HDAC expression in the brain. Based on
comparisons made between treatment groups, poten-
tially key mechanistic targets of acetate supplementation
include the LPS-induced changes in H3K9 acetylation,
the expression of HDAC7 and the pro-inflammatory
cytokine IL-1b. Thus physical epigenetic changes and/or
direct changes in protein acetylation may help to explain
the functional consequences of acetate supplementation
found in this model of neuroinflammation.
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